Nanomix (Nanomix) Debt-to-Asset : 11.62 (As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Nanomix Debt-to-Asset?

Nanomix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $1.30 Mil. Nanomix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $10.11 Mil. Nanomix's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2022 was $0.98 Mil. Nanomix's debt to asset for the quarter that ended in Dec. 2022 was 11.62.

Nanomix Debt-to-Asset Historical Data

The historical data trend for Nanomix's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanomix Debt-to-Asset Chart

Nanomix Annual Data

Trend

Dec20

Dec21

Dec22

Debt-to-Asset

17.58

5.31

11.62

Nanomix Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Debt-to-Asset	Get a 7-Day Free Trial						5.31	5.34	7.52	9.39	11.62

Competitive Comparison of Nanomix's Debt-to-Asset

For the Medical Devices subindustry, Nanomix's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanomix's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanomix's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Nanomix's Debt-to-Asset falls into.

Nanomix Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Nanomix's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.295	+	10.111)	/	0.982
	=	11.62

Nanomix's Debt-to-Asset for the quarter that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.295	+	10.111)	/	0.982
	=	11.62

Nanomix (OTCPK:NNMX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Nanomix Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Nanomix's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanomix (Nanomix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanomix Corp (OTCPK:NNMX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

2121 Williams Street, San Leandro, CA, USA, 94577

Website

https://www.nanomixdx.com

Nanomix Corp develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or monitor diseases. Its products include The Nanomix eLab System, COVID-19 Rapid Antigen Panel, and Critical Infection and Host Response. The company's products improve healthcare delivery by bringing the diagnostic information to the point of initial patient interaction, whether in the hospital or settings such as nursing facilities, elderly homes, urgent care centers, airports, schools, and more.

Executives

Chris Hetterly	officer: Chief Financial Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Garrett Gruener	director, 10 percent owner	ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Thomas Schlumpberger	director, officer: CEO	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Vidur Sahney	officer: Chief Operating Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
John Hardesky	officer: Chief Commercial Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
David Ludvigson	director, officer: CEO and President	BLACK PEARL INC, 400 SECOND ST STE 450, SAN FRANCISCO CA 94107
Gregory T Schiffman	director	1030 NW JOHNSON ST, UNIT 608, PORTLAND OR 97209
Loraine Upham	officer: Chief Operating Officer	C/O BOSTON THERAPEUTUCS INC., 354 MERRIMACK ST, #4, LAWRENCE MA 01843
Carl W Rausch	director, officer: CEO
Alan M Hoberman	director	6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Cheng Conroy Chi-heng	director	ADVANCE PHARMACEUTICAL CO LTD, 3/F, GMP CENTRE, 12 DAI FU STREET, TAI PO K3 280
Anthony Don Squeglia	officer: Chief Financial Officer	PRO-PHARMACEUTICALS, INC., 7 WELLS AVENUE, SUITE 34, NEWTON MA 02459
Neill Sydney Colin	director	C/O AXONYX INC, 500 SEVENTH AVE 1OTH FLOOR, NEW YORK NY 10018
Jonathan B Rome	officer: Chief Operating Officer (3)	178 WEST SADDLE RIVER ROAD, SADDLE RIVER NJ 07458
Rom E Eliaz	director	33 KACHAL STREET, LEHAVIM L3 85338